特发性肺纤维化患者肺移植术前后CA199改变
Changes of CA199 in Patients with Idiopathic Pulmonary Fibrosis before and after Lung Transplantation
DOI: 10.12677/ACM.2022.121013, PDF,   
作者: 李晓峰, 王广才, 李红艳, 闫凤岐*：解放军总医院京东医疗区光明桥门诊部，北京
关键词: 特发性肺纤维化；肿瘤标志物；肺移植；Idiopathic Pulmonary Fibrosis； Tumor Markers； Lung Transplantation
摘要: 目的：探讨特发性肺纤维化患者部分肿瘤标志物升高能否准确地描述其基本的进展程度和生存率。方法：通过对1例67岁患者肺移植前后10年的临床资料及肿瘤标志物的变化进行分析，并查阅相关文件进行分析。结果：患者肿瘤标志物CA199在肺移植手术指征前5年进行性升高，在肺移植前一年迅速增高，手术后恢复正常，而CA125手术前后值未有明显变化。结论：特发性肺纤维化患者肿瘤标志物CA199会升高，且值升高的程度跟疾病的恶化程度相关，值得临床关注。
Abstract: Objective: To investigate whether some tumor markers can accurately describe the basic progression and survival rate of patients with idiopathic pulmonary fibrosis. Methods: The clinical data and changes of tumor markers of a 67-year-old patient before and after lung transplantation in 10 years were analyzed, and relevant documents were consulted for analysis. Results: The tumor marker CA199 gradually increased 5 years before the indication of lung transplantation and returned to normal after operation. Conclusion: Some tumor markers in patients with idiopathic pulmonary fibrosis will increase, and the degree of increase is related to the deterioration of the disease.
文章引用：李晓峰, 王广才, 李红艳, 闫凤岐. 特发性肺纤维化患者肺移植术前后CA199改变[J]. 临床医学进展, 2022, 12(1): 74-77. https://doi.org/10.12677/ACM.2022.121013

参考文献

[1] Hutchinson, J., Fogarty, A., Hubbard, R., et al. (2015) Global Incidence and Mortality of Idiopathic Pulmonary Fibrosis: A Systematic Review. European Respiratory Journal, 46, 795-806. [Google Scholar] [CrossRef] [PubMed]
[2] Allen, R.J., Guillen-Guio, B., Oldham, J.M., et al. (2020) Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care, 201, 564-574. [Google Scholar] [CrossRef] 
[3] 曹淑芳, 蔡少华, 刘长庭. CA199显著升高的特发性肺纤维化一例——附文献复习[J]. 临床内科杂志, 2003, 20(6): 300-302.
[4] Rusanov, V., Kramer, M.R., Raviv, Y., et al. (2012) The Significance of Elevated Tumor Markers among Patients with Idiopathic Pulmonary Fibrosis Before and after Lung Transplantation. Chest, 141, 1047-1054. [Google Scholar] [CrossRef] [PubMed]
[5] 范宇斌, 何荣伶, 邹丽君, 等. 生物标志物在特发性肺纤维化中的临床价值[J]. 南方医科大学学报, 2020, 40(7): 1062-1064.
[6] 李双, 叶俏. 特发性肺纤维化的组学研究进展[J]. 中国药理学与毒理学杂志, 2020, 34(2): 153-160.
[7] 李少峰, 高洁, 刘志强, 等. 特发性肺纤维化与肿瘤标志物相关性分析[J]. 临床医药实践, 2020, 29(9): 643-646.
[8] Skandamis, A., Kani, C., Markantonis, S.L. and Souliotis, K. (2019) Systematic Review and Network Metaanalysis of Approved Medicines for the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Drug Assessment, 8, 55-61. [Google Scholar] [CrossRef] [PubMed]
[9] Varone, F., Sgalla, G., Iovene, B., et al. (2018) Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. Expert Opinion on Pharmacotherapy, 19, 167-175. [Google Scholar] [CrossRef] [PubMed]
[10] Obayashi, Y., Takehiko, F., Nishiyama, T., et al. (2000) Role of Carbohydrate Antigens Sialyl Lewis (a) (CA19-9) in Bronchoalveolar Lavage in Patients with Pulmonary Fibrosis. Respiration, 67, 146-152. [Google Scholar] [CrossRef] [PubMed]

为你推荐